TriangleQuizartinib High Dose (NCT06824168)
Quizartinib High Dose trial for Acute Myeloid Leukemia (NCT06824168). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with FLT3-ITD acute myeloid leukemia in first complete remission after chemotherapy, without a donor stem-cell transplant. Therapy-related leukemia is excluded.
The idea: quizartinib blocks FLT3 growth signals in leukemia cells. Patients take it daily by mouth as maintenance, randomly assigned to a higher or lower dose. Dose amounts are not published. Researchers primarily track serious treatment-emergent adverse events and also study remission duration.
This phase 2 study plans 130 patients. Daiichi Sankyo sponsors it; five US sites are recruiting, including Houston.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.